Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial (Q47635702)

4 February 2018

title

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial (English)

1 reference

4 February 2018

main subject

phase II clinical trial

0 references

1 reference

16

1 reference

4 February 2018

Javier de la Rubia

25

1 reference

4 February 2018

Sagar Lonial

1

Sagar Lonial

1 reference

4 February 2018

26

Paul G Richardson

1 reference

4 February 2018

Robert Z Orlowski

12

Robert Z Orlowski

1 reference

4 February 2018

Brendan M Weiss

2

Brendan M Weiss

1 reference

4 February 2018

Saad Z Usmani

3

Saad Z Usmani

1 reference

4 February 2018

Nizar J Bahlis

6

Nizar J Bahlis

1 reference

4 February 2018

Amrita Y Krishnan

8

Amrita Krishnan

1 reference

4 February 2018

Joan Bladé

14

Joan Bladé

1 reference

4 February 2018

María Victoria Mateos

10

Maria Victoria Mateos

1 reference

4 February 2018

Steen Lisby

27

Steen Lisby

1 reference

4 February 2018

Seema Singhal

4

Seema Singhal

1 reference

4 February 2018

Ajai Chari

5

Ajai Chari

1 reference

4 February 2018

Natalie Callander

22

Natalie Callander

1 reference

4 February 2018

author name string

Andrew Belch

7

1 reference

4 February 2018

Robert A Vescio

9

1 reference

4 February 2018

Amitabha Mazumder

11

1 reference

4 February 2018

Heather J Sutherland

13

1 reference

4 February 2018

Emma C Scott

15

1 reference

4 February 2018

Jesus Berdeja

17

1 reference

4 February 2018

Mecide Gharibo

18

1 reference

4 February 2018

Don A Stevens

19

1 reference

4 February 2018

Richard LeBlanc

20

1 reference

4 February 2018

Michael Sebag

21

1 reference

4 February 2018

Andrzej Jakubowiak

23

1 reference

4 February 2018

Darrell White

24

1 reference

4 February 2018

Huaibao Feng

28

1 reference

4 February 2018

Clarissa M Uhlar

29

1 reference

4 February 2018

Imran Khan

30

1 reference

4 February 2018

Tahamtan Ahmadi

31

1 reference

4 February 2018

Peter M Voorhees

32

1 reference

4 February 2018

language of work or name

English

0 references

publication date

6 January 2016

1 reference

4 February 2018

published in

The Lancet

1 reference

4 February 2018

volume

387

1 reference

4 February 2018

issue

10027

1 reference

4 February 2018

page(s)

1551-1560

1 reference

4 February 2018

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

1 reference

7 January 2021

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Resolving the daratumumab interference with blood compatibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

IMWG consensus on risk stratification in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901120-4

7 January 2021

10.1016/S0140-6736(15)01120-4

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018